An observational study in Colorectal Cancer, sponsored by University Hospital, Ioannina. Completed at 1 site in Greece. Open to participants aged 25 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by University Hospital, Ioannina · Observational
This study was designed to investigate the efficacy of flow cytometry to accurately identify between normal and cancer cells in colon epithelium in humans diagnosed with colorectal cancer.
Tissue samples from normal and cancerous colon epithelium are collected intraoperatively following standard colectomy and analyzed blindly by flow cytometry, which reports, in less than 10 min, on the origin of the sample based in the estimation of DNA and tumor index.
5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,459 are open to participants now.
This study's enrollment of 106 is below the median of 250 across 1,226 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →University Hospital, Ioannina is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients diagnosed with colorectal cancer and being treated by standard colectomy or/and neoadjuvant theraphy according to current guidelines.
biopsy proven colorectal cancer signed informed consent for participation
Exclusion Criteria:
Tissue samples from normal colorectal epithelium are collected during colectomy in every colorectal cancer patient
Diagnostic Test: flow cytometry
Tissue samples from colorectal cancer are collected during colectomy in every colorectal cancer patient
Diagnostic Test: flow cytometry
evaluation of intraoperative flow cytometry in detecting cancer cells in colorectal epithelium
Accuracy of intraoperative Flow Cytometry for cancer cell identification in colorectal cancer.
Samples from cancer and normal colon epithelium are prospectively collected intraoperatively and assessed with intraoperative Flow Cytometry. Following comparative DNA content and phenotypic analysis, the receiver operating characteristic (ROC) curve analysis is used to evaluate the performance of intraoperative Flow Cytometry to distinguish between normal and cancer tissue. The optimal cut-off value is determined to delineate the status of tumor tissue, resulting in the highest sensitivity and specificity and hence the optimal accuracy.
Time frame: 2017-2021
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Ioannina